STANDUP-HF
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients with HF and Impaired Systoli
- Stage
- klaar
- Medicine
- BMS-986231
- Population
- Hartfalen
- Phase
- II
- First Patient In
- 1 October 2017
- Last Patient In
- 31 May 2019
- Last Patient Last Visit
- 7 November 2019
National Lead
